1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAims to accelerate cancer research, including AI-driven approaches for prevention and early detection.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U. S. organizations, including small businesses. Confirm the full requirements in the official notice before applying.
Cancer Moonshot Initiative is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
The Cancer Immunoprevention Research Projects grant, part of the National Cancer Institute's Cancer Moonshot Initiative, funds innovative research into preventing cancer through immunological approaches. The NCI supports projects addressing cancer immunoprevention, with a focus on interdisciplinary and international scientific collaboration. Eligible applicants include nonprofits with 501(c)(3) status, state governments, tribal governments, city and township governments, and private institutions. The program also supports early-stage investigators through the MERIT R37 award pathway. Specific award amounts and application deadlines vary by funding opportunity announcement.
Yang Immune Innovation Fund is sponsored by UCLA Health. The Yang Immune Innovation Fund aims to accelerate investigations and expand research operations into a comprehensive program in translational immunology. Through private philanthropy, the fund supports research concepts in infectious diseases, cancer, and organ transplantation, focusing on 'moonshot ideas' with transformative potential in harnessing and controlling the immune system.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article